Fennec Pharmaceuticals (TSX:FRX) Beta: 3.5181 (As of Jun. 24, 2026)


TSX:FRX Fennec Pharmaceuticals Inc TSX:FRX
54 GF Score
Price C$14.74
GF Value C$14.13
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Fennec Pharmaceuticals Beta?

Fennec Pharmaceuticals TSX:FRX +0.89% 54 Beta is 3.5181 as of Jun. 24, 2026. GuruFocus rates TSX:FRX with a GF Score™ of 54/100 and a GF Value™ of C$14.13 (Fairly Valued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-24), Fennec Pharmaceuticals's Beta is 3.5181.


Fennec Pharmaceuticals  (TSX:FRX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Fennec Pharmaceuticals Beta Related Terms


Fennec Pharmaceuticals Beta Historical Data

* Premium members only.

The historical data trend for Fennec Pharmaceuticals's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fennec Pharmaceuticals Beta Chart

Fennec Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.16 -0.06 0.71 1.03 2.78

Fennec Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.08 2.15 2.48 2.78 3.09

TSX:FRX vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Fennec Pharmaceuticals's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Beta distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Beta falls into.


TSX:FRX
54GF Score
Fennec Pharmaceuticals Inc TSX:FRX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fennec Pharmaceuticals Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 3.5181 mean?
Fennec Pharmaceuticals (TSX:FRX) has a Beta of 3.5181 as of Jun. 24, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Fennec Pharmaceuticals and its competitors.
Is Fennec Pharmaceuticals' Beta too high?
Fennec Pharmaceuticals' current Beta is 3.5181. Overall, Fennec Pharmaceuticals has a GF Score™ of 54/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fennec Pharmaceuticals' Beta compare to VRTX and REGN?
Fennec Pharmaceuticals' Beta of 3.5181 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Fennec Pharmaceuticals and its competitors. Fennec Pharmaceuticals's current Beta is 3.5181. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fennec Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Fennec Pharmaceuticals (TSX:FRX) is currently considered Fairly Valued. The stock's GF Value™ is C$14.13, compared to a current price of C$14.74 — trading 4.3% above its estimated fair value. The current Beta is 3.5181. Fennec Pharmaceuticals' overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Fennec Pharmaceuticals (TSX:FRX), the current Beta is 3.5181 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fennec Pharmaceuticals (TSX:FRX) Overvalued in 2026?

Based on GuruFocus' analysis, Fennec Pharmaceuticals stock appears to be overvalued. The current stock price of C$14.74 is trading 4.3% above its estimated GF Value™ of C$14.13. GuruFocus considers Fennec Pharmaceuticals to be Fairly Valued.

Key valuation signals for TSX:FRX:

  • Beta: 3.5181
  • GF Value™: C$14.13 vs. price of C$14.74 (4.3% above fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the TSX:FRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fennec Pharmaceuticals Business Description

Other Exchanges FENC:USARV41:Germany
Address 68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
54GF Score

Get the complete analysis for TSX:FRX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$14.74
Price
C$14.13
GF Value